Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer
The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured b...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2023-07, Vol.23 (1), p.646 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 646 |
| container_title | BMC cancer |
| container_volume | 23 |
| creator | Ottestad, Anine Larsen Johansen, Håkon Halvorsen, Tarje Onsøien Dai, Hong Yan Wahl, Sissel Gyrid Freim Emdal, Elisabeth Fritzke Grønberg, Bjørn Henning |
| description | The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured by
F-fluorodeoxyglucose positron emission tomography (
F-FDG PET/CT). This study investigated this association in NSCLC patients considered for potentially curative treatment and explored whether the two methods provide independent prognostic information.
Patients with stage I-III NSCLC who had routinely undergone an
F-FDG PET/CT scan and exploratory ctDNA analyses were included. Tumor glucose uptake was measured by maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from the
F-FDG PET/CT scans. ctDNA detectability and quantity, using variant allele frequency, were estimated by tumor-informed ctDNA analyses.
In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA (n = 19, p |
| doi_str_mv | 10.1186/s12885-023-11147-z |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_37434111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>37434111</sourcerecordid><originalsourceid>FETCH-pubmed_primary_374341113</originalsourceid><addsrcrecordid>eNqFj81OwzAQhC0kRMvPC3BA-wKmdhKIr1Xb0BPikHu1cZYo4DiR1xYKz8EDk0M5c5lPoxlpNELca_WotXnesM6MeZIqy6XWuijl94VYL9QyK1S5EtfMH0rp0ihzJVZ5WeTF0luLny3zaHuM_egZGopfRB5aimQjNo7A9sEmt-S-g5iGMcD-dQvo27PrXLIjE6Qp4ifBQMgpUAvNDNpAJav9C7wd6s2uht4DYXCz5IgdgR-95AGdA0uLuLQsWPSWwq24fEfHdHfmjXioDvXuKKfUDNSeptAPGObT343838Ivg0ZZZg</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Ottestad, Anine Larsen ; Johansen, Håkon ; Halvorsen, Tarje Onsøien ; Dai, Hong Yan ; Wahl, Sissel Gyrid Freim ; Emdal, Elisabeth Fritzke ; Grønberg, Bjørn Henning</creator><creatorcontrib>Ottestad, Anine Larsen ; Johansen, Håkon ; Halvorsen, Tarje Onsøien ; Dai, Hong Yan ; Wahl, Sissel Gyrid Freim ; Emdal, Elisabeth Fritzke ; Grønberg, Bjørn Henning</creatorcontrib><description>The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured by
F-fluorodeoxyglucose positron emission tomography (
F-FDG PET/CT). This study investigated this association in NSCLC patients considered for potentially curative treatment and explored whether the two methods provide independent prognostic information.
Patients with stage I-III NSCLC who had routinely undergone an
F-FDG PET/CT scan and exploratory ctDNA analyses were included. Tumor glucose uptake was measured by maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from the
F-FDG PET/CT scans. ctDNA detectability and quantity, using variant allele frequency, were estimated by tumor-informed ctDNA analyses.
In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA (n = 19, p < 0.001). The ctDNA quantity correlated with MTV (Spearman's ρ = 0.53, p = 0.021) and TLG (Spearman's ρ = 0.56, p = 0.013) but not with SUVmax (Spearman's ρ = 0.034, p = 0.15). ctDNA detection was associated with shorter OS independent of MTV (HR: 2.70, 95% CI: 1.07-6.82, p = 0.035) and TLG (HR: 2.63, 95% CI: 1.06-6.51, p = 0.036). Patients with high tumor glucose uptake and detectable ctDNA had shorter overall survival and progression-free survival than those without detectable ctDNA, though these associations were not statistically significant (p > 0.05).
There was a positive correlation between plasma ctDNA quantity and MTV and TLG in early-stage NSCLC patients. Despite the correlation, the results indicated that ctDNA detection was a negative prognostic factor independent of MTV and TLG.</description><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-023-11147-z</identifier><identifier>PMID: 37434111</identifier><language>eng</language><publisher>England</publisher><ispartof>BMC cancer, 2023-07, Vol.23 (1), p.646</ispartof><rights>2023. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,862,27913,27914</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37434111$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ottestad, Anine Larsen</creatorcontrib><creatorcontrib>Johansen, Håkon</creatorcontrib><creatorcontrib>Halvorsen, Tarje Onsøien</creatorcontrib><creatorcontrib>Dai, Hong Yan</creatorcontrib><creatorcontrib>Wahl, Sissel Gyrid Freim</creatorcontrib><creatorcontrib>Emdal, Elisabeth Fritzke</creatorcontrib><creatorcontrib>Grønberg, Bjørn Henning</creatorcontrib><title>Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured by
F-fluorodeoxyglucose positron emission tomography (
F-FDG PET/CT). This study investigated this association in NSCLC patients considered for potentially curative treatment and explored whether the two methods provide independent prognostic information.
Patients with stage I-III NSCLC who had routinely undergone an
F-FDG PET/CT scan and exploratory ctDNA analyses were included. Tumor glucose uptake was measured by maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from the
F-FDG PET/CT scans. ctDNA detectability and quantity, using variant allele frequency, were estimated by tumor-informed ctDNA analyses.
In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA (n = 19, p < 0.001). The ctDNA quantity correlated with MTV (Spearman's ρ = 0.53, p = 0.021) and TLG (Spearman's ρ = 0.56, p = 0.013) but not with SUVmax (Spearman's ρ = 0.034, p = 0.15). ctDNA detection was associated with shorter OS independent of MTV (HR: 2.70, 95% CI: 1.07-6.82, p = 0.035) and TLG (HR: 2.63, 95% CI: 1.06-6.51, p = 0.036). Patients with high tumor glucose uptake and detectable ctDNA had shorter overall survival and progression-free survival than those without detectable ctDNA, though these associations were not statistically significant (p > 0.05).
There was a positive correlation between plasma ctDNA quantity and MTV and TLG in early-stage NSCLC patients. Despite the correlation, the results indicated that ctDNA detection was a negative prognostic factor independent of MTV and TLG.</description><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFj81OwzAQhC0kRMvPC3BA-wKmdhKIr1Xb0BPikHu1cZYo4DiR1xYKz8EDk0M5c5lPoxlpNELca_WotXnesM6MeZIqy6XWuijl94VYL9QyK1S5EtfMH0rp0ihzJVZ5WeTF0luLny3zaHuM_egZGopfRB5aimQjNo7A9sEmt-S-g5iGMcD-dQvo27PrXLIjE6Qp4ifBQMgpUAvNDNpAJav9C7wd6s2uht4DYXCz5IgdgR-95AGdA0uLuLQsWPSWwq24fEfHdHfmjXioDvXuKKfUDNSeptAPGObT343838Ivg0ZZZg</recordid><startdate>20230711</startdate><enddate>20230711</enddate><creator>Ottestad, Anine Larsen</creator><creator>Johansen, Håkon</creator><creator>Halvorsen, Tarje Onsøien</creator><creator>Dai, Hong Yan</creator><creator>Wahl, Sissel Gyrid Freim</creator><creator>Emdal, Elisabeth Fritzke</creator><creator>Grønberg, Bjørn Henning</creator><scope>NPM</scope></search><sort><creationdate>20230711</creationdate><title>Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer</title><author>Ottestad, Anine Larsen ; Johansen, Håkon ; Halvorsen, Tarje Onsøien ; Dai, Hong Yan ; Wahl, Sissel Gyrid Freim ; Emdal, Elisabeth Fritzke ; Grønberg, Bjørn Henning</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_374341113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ottestad, Anine Larsen</creatorcontrib><creatorcontrib>Johansen, Håkon</creatorcontrib><creatorcontrib>Halvorsen, Tarje Onsøien</creatorcontrib><creatorcontrib>Dai, Hong Yan</creatorcontrib><creatorcontrib>Wahl, Sissel Gyrid Freim</creatorcontrib><creatorcontrib>Emdal, Elisabeth Fritzke</creatorcontrib><creatorcontrib>Grønberg, Bjørn Henning</creatorcontrib><collection>PubMed</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ottestad, Anine Larsen</au><au>Johansen, Håkon</au><au>Halvorsen, Tarje Onsøien</au><au>Dai, Hong Yan</au><au>Wahl, Sissel Gyrid Freim</au><au>Emdal, Elisabeth Fritzke</au><au>Grønberg, Bjørn Henning</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2023-07-11</date><risdate>2023</risdate><volume>23</volume><issue>1</issue><spage>646</spage><pages>646-</pages><eissn>1471-2407</eissn><abstract>The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic NSCLC indicate that ctDNA levels are associated with tumor metabolic activity as measured by
F-fluorodeoxyglucose positron emission tomography (
F-FDG PET/CT). This study investigated this association in NSCLC patients considered for potentially curative treatment and explored whether the two methods provide independent prognostic information.
Patients with stage I-III NSCLC who had routinely undergone an
F-FDG PET/CT scan and exploratory ctDNA analyses were included. Tumor glucose uptake was measured by maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from the
F-FDG PET/CT scans. ctDNA detectability and quantity, using variant allele frequency, were estimated by tumor-informed ctDNA analyses.
In total, 63 patients (median age 70 years, 60% women, and 90% adenocarcinoma) were included. The tumor glucose uptake (SUVmax, MTV, and TLG) was significantly higher in patients with detectable ctDNA (n = 19, p < 0.001). The ctDNA quantity correlated with MTV (Spearman's ρ = 0.53, p = 0.021) and TLG (Spearman's ρ = 0.56, p = 0.013) but not with SUVmax (Spearman's ρ = 0.034, p = 0.15). ctDNA detection was associated with shorter OS independent of MTV (HR: 2.70, 95% CI: 1.07-6.82, p = 0.035) and TLG (HR: 2.63, 95% CI: 1.06-6.51, p = 0.036). Patients with high tumor glucose uptake and detectable ctDNA had shorter overall survival and progression-free survival than those without detectable ctDNA, though these associations were not statistically significant (p > 0.05).
There was a positive correlation between plasma ctDNA quantity and MTV and TLG in early-stage NSCLC patients. Despite the correlation, the results indicated that ctDNA detection was a negative prognostic factor independent of MTV and TLG.</abstract><cop>England</cop><pmid>37434111</pmid><doi>10.1186/s12885-023-11147-z</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1471-2407 |
| ispartof | BMC cancer, 2023-07, Vol.23 (1), p.646 |
| issn | 1471-2407 |
| language | eng |
| recordid | cdi_pubmed_primary_37434111 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; PubMed Central |
| title | Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18 F-FDG PET/CT in early-stage non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A08%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Associations%20between%20detectable%20circulating%20tumor%20DNA%20and%20tumor%20glucose%20uptake%20measured%20by%2018%20F-FDG%20PET/CT%20in%20early-stage%20non-small%20cell%20lung%20cancer&rft.jtitle=BMC%20cancer&rft.au=Ottestad,%20Anine%20Larsen&rft.date=2023-07-11&rft.volume=23&rft.issue=1&rft.spage=646&rft.pages=646-&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-023-11147-z&rft_dat=%3Cpubmed%3E37434111%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/37434111&rfr_iscdi=true |